Bristol Myers Squibb has expanded its push into radiopharmaceuticals by licensing a prostate cancer therapy developed by Swiss biotech Philochem in a deal that includes an upfront payment of $350 ...
Bristol Myers Squibb has reached for its wallet to avoid being left behind in the race to develop a new class of bispecific antibodies for cancer that have been billed as the next big thing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results